What do systematic reviews say?

Continuous vs Intermittent Antibiotic Infusions

Continuous showed no clear difference in all‐cause mortality compared with intermittent Antibiotic Infusions (moderate certainty).

• Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections 2013 · Cochrane Headline outcomes only
  RR 0.89 [0.67, 1.2]
  19 studies · 1241 participants
  Moderate

Continuous veno‐venous hemofiltration (CVVH) vs no CVVH

• Continuous veno‐venous hemofiltration for severe acute pancreatitis 2019 · Cochrane Headline outcomes only
  0.62 [0.27, 1.4]
  2 studies · 189 participants
  Very low

High‐volume continuous veno‐venous hemofiltration (CVVH) vs standard CVVH

High‐volume continuous veno‐venous hemofiltration (CVVH) showed no clear difference in all‐cause mortality compared with standard CVVH (low certainty).

• Continuous veno‐venous hemofiltration for severe acute pancreatitis 2019 · Cochrane Headline outcomes only
  RR 0.6 [0.17, 2.07]
  1 study · 30 participants
  Low

Continuous infusion vs bolus administration

The review found no eligible studies for this question.

• Systemic opioid regimens for postoperative pain in neonates 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Continuous infusion of intravenous loop diuretics vs bolus injection of intravenous loop diuretics

Summary of findings table ‐ Continuous infusion of intravenous loop… showed no clear difference in all‐cause mortality (from admission to discharge) compared with bolus injection of intravenous loop diuretics (low certainty).

• Continuous infusion versus bolus injection of loop diuretics for acute heart failure 2024 · Cochrane Headline outcomes only
  RR 1.53 [0.81, 2.9]
  5 studies · 530 participants
  Low

Continuous glucose monitoring system vs intermittent modalities

It is very uncertain whether summary of findings table ‐ Continuous glucose monitoring (CGM) changes death during initial hospitalization (all‐cause mortality) compared with intermittent modalities (very low certainty).

• Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants 2021 · Cochrane Headline outcomes only
  RR 0.59 [0.16, 2.13]
  2 studies · 230 participants
  Very low

Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care

It is very uncertain whether continuous positive airway pressure (CPAP) plus best supportive care changes all‐cause mortality ‐ after 24 months Number of participants: 287(2… compared with best supportive care (very low certainty).

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  RR 1.14 [0.83, 1.56]
  Studies not reported
  Very low

Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP)

The review found no eligible studies for this question.

• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Non‐invasive positive pressure ventilation for central sleep apnoea in adults 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bubble vs ventilator or Infant Flow Driver nasal continuous positive airway pressure (CPAP)

Bubble showed no clear difference in all‐cause mortality before hospital discharge compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).

• Bubble devices versus other pressure sources for nasal continuous positive airway pressure in preterm infants 2023 · Cochrane Headline outcomes only
  RR 0.93 [0.64, 1.36]
  10 studies · 1189 participants
  Low

Mask vs prongs

Mask showed no clear difference in all‐cause mortality compared with prongs (low certainty).

• Masks versus prongs as interfaces for nasal continuous positive airway pressure in preterm infants 2022 · Cochrane Headline outcomes only
  RR 0.83 [0.56, 1.22]
  7 studies · 814 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in all‐cause mortality (low certainty).

• Continuous renal replacement therapy (CRRT) for rhabdomyolysis 2014 · Cochrane Headline outcomes only
  RR 0.17 [0.02, 1.37]
  1 study · 43 participants
  Low